= 0.002), while no treatment reduced LOS.ConclusionsAmong evaluated osteobiologics, rhBMP-2 demonstrated superior efficacy and safety compared to AICBG in posterior LSF. Other agents showed favourable trends without statistical significance, reflecting persistent uncertainty rather than confirmed equivalence.
Ambrosio et al. (Wed,) studied this question.